nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—ERBB3—chronic obstructive pulmonary disease	0.38	0.69	CbGaD
Bosutinib—EGFR—chronic obstructive pulmonary disease	0.17	0.309	CbGaD
Bosutinib—Vandetanib—ERBB3—chronic obstructive pulmonary disease	0.00157	0.258	CrCbGaD
Bosutinib—Gefitinib—ERBB3—chronic obstructive pulmonary disease	0.0015	0.245	CrCbGaD
Bosutinib—Vandetanib—VEGFA—chronic obstructive pulmonary disease	0.000837	0.137	CrCbGaD
Bosutinib—Vandetanib—EGFR—chronic obstructive pulmonary disease	0.000706	0.116	CrCbGaD
Bosutinib—Gefitinib—EGFR—chronic obstructive pulmonary disease	0.000671	0.11	CrCbGaD
Bosutinib—STK4—connective tissue—chronic obstructive pulmonary disease	0.000671	0.00483	CbGeAlD
Bosutinib—ROCK1—respiratory system—chronic obstructive pulmonary disease	0.000664	0.00479	CbGeAlD
Bosutinib—PLK2—bronchus—chronic obstructive pulmonary disease	0.000656	0.00473	CbGeAlD
Bosutinib—BMPR2—respiratory system—chronic obstructive pulmonary disease	0.000645	0.00465	CbGeAlD
Bosutinib—PLK2—smooth muscle tissue—chronic obstructive pulmonary disease	0.000642	0.00463	CbGeAlD
Bosutinib—WEE1—trachea—chronic obstructive pulmonary disease	0.000634	0.00457	CbGeAlD
Bosutinib—DMPK—trachea—chronic obstructive pulmonary disease	0.000634	0.00457	CbGeAlD
Bosutinib—TYRO3—connective tissue—chronic obstructive pulmonary disease	0.000634	0.00457	CbGeAlD
Bosutinib—ALK—connective tissue—chronic obstructive pulmonary disease	0.000634	0.00457	CbGeAlD
Bosutinib—LYN—connective tissue—chronic obstructive pulmonary disease	0.00063	0.00455	CbGeAlD
Bosutinib—MAP4K4—respiratory system—chronic obstructive pulmonary disease	0.000621	0.00448	CbGeAlD
Bosutinib—CAMK1D—bronchus—chronic obstructive pulmonary disease	0.000619	0.00447	CbGeAlD
Bosutinib—BTK—connective tissue—chronic obstructive pulmonary disease	0.000618	0.00445	CbGeAlD
Bosutinib—BCR—respiratory system—chronic obstructive pulmonary disease	0.000616	0.00445	CbGeAlD
Bosutinib—STK24—bronchus—chronic obstructive pulmonary disease	0.000612	0.00442	CbGeAlD
Bosutinib—STK25—trachea—chronic obstructive pulmonary disease	0.000605	0.00437	CbGeAlD
Bosutinib—MAP2K1—respiratory system—chronic obstructive pulmonary disease	0.0006	0.00432	CbGeAlD
Bosutinib—CSK—respiratory system—chronic obstructive pulmonary disease	0.000596	0.0043	CbGeAlD
Bosutinib—FER—bronchus—chronic obstructive pulmonary disease	0.000592	0.00427	CbGeAlD
Bosutinib—CSNK1A1—respiratory system—chronic obstructive pulmonary disease	0.000592	0.00427	CbGeAlD
Bosutinib—PLK2—trachea—chronic obstructive pulmonary disease	0.000589	0.00425	CbGeAlD
Bosutinib—CLK1—respiratory system—chronic obstructive pulmonary disease	0.000588	0.00424	CbGeAlD
Bosutinib—ROCK1—connective tissue—chronic obstructive pulmonary disease	0.000585	0.00422	CbGeAlD
Bosutinib—MAP4K1—bronchus—chronic obstructive pulmonary disease	0.00058	0.00419	CbGeAlD
Bosutinib—BTK—bronchus—chronic obstructive pulmonary disease	0.000578	0.00416	CbGeAlD
Bosutinib—CAMK2G—respiratory system—chronic obstructive pulmonary disease	0.000577	0.00416	CbGeAlD
Bosutinib—LRRK2—respiratory system—chronic obstructive pulmonary disease	0.000572	0.00413	CbGeAlD
Bosutinib—TLK1—lung—chronic obstructive pulmonary disease	0.00057	0.00411	CbGeAlD
Bosutinib—BMPR2—connective tissue—chronic obstructive pulmonary disease	0.000568	0.00409	CbGeAlD
Bosutinib—PRKCQ—lung—chronic obstructive pulmonary disease	0.000562	0.00405	CbGeAlD
Bosutinib—PTK2B—respiratory system—chronic obstructive pulmonary disease	0.000558	0.00402	CbGeAlD
Bosutinib—CAMK1D—trachea—chronic obstructive pulmonary disease	0.000556	0.00401	CbGeAlD
Bosutinib—STK33—lung—chronic obstructive pulmonary disease	0.000554	0.004	CbGeAlD
Bosutinib—STK3—bronchus—chronic obstructive pulmonary disease	0.000554	0.00399	CbGeAlD
Bosutinib—STK24—trachea—chronic obstructive pulmonary disease	0.00055	0.00396	CbGeAlD
Bosutinib—CSNK1E—respiratory system—chronic obstructive pulmonary disease	0.000549	0.00396	CbGeAlD
Bosutinib—MAP4K4—connective tissue—chronic obstructive pulmonary disease	0.000547	0.00394	CbGeAlD
Bosutinib—SIK1—respiratory system—chronic obstructive pulmonary disease	0.00054	0.00389	CbGeAlD
Bosutinib—ROCK1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000535	0.00386	CbGeAlD
Bosutinib—FER—trachea—chronic obstructive pulmonary disease	0.000532	0.00384	CbGeAlD
Bosutinib—BMPR2—bronchus—chronic obstructive pulmonary disease	0.000531	0.00383	CbGeAlD
Bosutinib—ERBB3—respiratory system—chronic obstructive pulmonary disease	0.000529	0.00382	CbGeAlD
Bosutinib—MAP2K2—respiratory system—chronic obstructive pulmonary disease	0.000528	0.00381	CbGeAlD
Bosutinib—MAP2K1—connective tissue—chronic obstructive pulmonary disease	0.000528	0.00381	CbGeAlD
Bosutinib—CLK3—lung—chronic obstructive pulmonary disease	0.000527	0.0038	CbGeAlD
Bosutinib—BMX—lung—chronic obstructive pulmonary disease	0.000527	0.0038	CbGeAlD
Bosutinib—DSTYK—lung—chronic obstructive pulmonary disease	0.000527	0.0038	CbGeAlD
Bosutinib—EPHB3—bronchus—chronic obstructive pulmonary disease	0.000527	0.0038	CbGeAlD
Bosutinib—STK36—bronchus—chronic obstructive pulmonary disease	0.000527	0.0038	CbGeAlD
Bosutinib—CSK—connective tissue—chronic obstructive pulmonary disease	0.000524	0.00378	CbGeAlD
Bosutinib—BMPR2—smooth muscle tissue—chronic obstructive pulmonary disease	0.000519	0.00375	CbGeAlD
Bosutinib—CLK1—connective tissue—chronic obstructive pulmonary disease	0.000518	0.00373	CbGeAlD
Bosutinib—CASK—lung—chronic obstructive pulmonary disease	0.000515	0.00372	CbGeAlD
Bosutinib—TBK1—respiratory system—chronic obstructive pulmonary disease	0.000513	0.0037	CbGeAlD
Bosutinib—PTK2—respiratory system—chronic obstructive pulmonary disease	0.000513	0.0037	CbGeAlD
Bosutinib—MAP4K4—bronchus—chronic obstructive pulmonary disease	0.000511	0.00368	CbGeAlD
Bosutinib—EIF2AK1—lung—chronic obstructive pulmonary disease	0.00051	0.00368	CbGeAlD
Bosutinib—BMP2K—connective tissue—chronic obstructive pulmonary disease	0.000508	0.00366	CbGeAlD
Bosutinib—BCR—bronchus—chronic obstructive pulmonary disease	0.000507	0.00366	CbGeAlD
Bosutinib—SRMS—lung—chronic obstructive pulmonary disease	0.000504	0.00364	CbGeAlD
Bosutinib—MAP3K12—bronchus—chronic obstructive pulmonary disease	0.000504	0.00363	CbGeAlD
Bosutinib—MAP4K4—smooth muscle tissue—chronic obstructive pulmonary disease	0.0005	0.00361	CbGeAlD
Bosutinib—TXK—lung—chronic obstructive pulmonary disease	0.000499	0.0036	CbGeAlD
Bosutinib—FES—lung—chronic obstructive pulmonary disease	0.000494	0.00356	CbGeAlD
Bosutinib—VRK2—lung—chronic obstructive pulmonary disease	0.000494	0.00356	CbGeAlD
Bosutinib—RPS6KB1—respiratory system—chronic obstructive pulmonary disease	0.000494	0.00356	CbGeAlD
Bosutinib—EPHB2—Diflorasone—Prednisone—chronic obstructive pulmonary disease	0.000493	0.212	CbGdCrCtD
Bosutinib—FGR—respiratory system—chronic obstructive pulmonary disease	0.000491	0.00354	CbGeAlD
Bosutinib—PTK2B—connective tissue—chronic obstructive pulmonary disease	0.000491	0.00354	CbGeAlD
Bosutinib—CSK—bronchus—chronic obstructive pulmonary disease	0.00049	0.00354	CbGeAlD
Bosutinib—AXL—respiratory system—chronic obstructive pulmonary disease	0.000489	0.00353	CbGeAlD
Bosutinib—CSNK1A1—bronchus—chronic obstructive pulmonary disease	0.000487	0.00351	CbGeAlD
Bosutinib—SYK—lung—chronic obstructive pulmonary disease	0.000485	0.00349	CbGeAlD
Bosutinib—TNIK—lung—chronic obstructive pulmonary disease	0.000485	0.00349	CbGeAlD
Bosutinib—HCK—bronchus—chronic obstructive pulmonary disease	0.000484	0.00349	CbGeAlD
Bosutinib—CLK1—bronchus—chronic obstructive pulmonary disease	0.000484	0.00349	CbGeAlD
Bosutinib—MAP2K1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000483	0.00348	CbGeAlD
Bosutinib—EPHB2—Diflorasone—Prednisolone—chronic obstructive pulmonary disease	0.000482	0.206	CbGdCrCtD
Bosutinib—CDK2—lung—chronic obstructive pulmonary disease	0.00048	0.00346	CbGeAlD
Bosutinib—CSK—smooth muscle tissue—chronic obstructive pulmonary disease	0.00048	0.00346	CbGeAlD
Bosutinib—CSNK1A1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000477	0.00344	CbGeAlD
Bosutinib—STK26—lung—chronic obstructive pulmonary disease	0.000476	0.00343	CbGeAlD
Bosutinib—SIK1—connective tissue—chronic obstructive pulmonary disease	0.000475	0.00343	CbGeAlD
Bosutinib—BMP2K—bronchus—chronic obstructive pulmonary disease	0.000475	0.00343	CbGeAlD
Bosutinib—STK36—trachea—chronic obstructive pulmonary disease	0.000473	0.00341	CbGeAlD
Bosutinib—EPHB3—trachea—chronic obstructive pulmonary disease	0.000473	0.00341	CbGeAlD
Bosutinib—EPHB4—respiratory system—chronic obstructive pulmonary disease	0.000467	0.00337	CbGeAlD
Bosutinib—ERBB3—connective tissue—chronic obstructive pulmonary disease	0.000466	0.00336	CbGeAlD
Bosutinib—MAP3K2—connective tissue—chronic obstructive pulmonary disease	0.000461	0.00333	CbGeAlD
Bosutinib—CHEK2—lung—chronic obstructive pulmonary disease	0.000459	0.00331	CbGeAlD
Bosutinib—MAP4K4—trachea—chronic obstructive pulmonary disease	0.000459	0.00331	CbGeAlD
Bosutinib—EPHA2—respiratory system—chronic obstructive pulmonary disease	0.000458	0.0033	CbGeAlD
Bosutinib—FYN—respiratory system—chronic obstructive pulmonary disease	0.000458	0.0033	CbGeAlD
Bosutinib—WEE1—lung—chronic obstructive pulmonary disease	0.000456	0.00329	CbGeAlD
Bosutinib—DMPK—lung—chronic obstructive pulmonary disease	0.000456	0.00329	CbGeAlD
Bosutinib—BCR—trachea—chronic obstructive pulmonary disease	0.000456	0.00329	CbGeAlD
Bosutinib—NUAK2—trachea—chronic obstructive pulmonary disease	0.000456	0.00329	CbGeAlD
Bosutinib—PTK2—connective tissue—chronic obstructive pulmonary disease	0.000452	0.00326	CbGeAlD
Bosutinib—CSNK1E—bronchus—chronic obstructive pulmonary disease	0.000451	0.00325	CbGeAlD
Bosutinib—PTK2B—smooth muscle tissue—chronic obstructive pulmonary disease	0.000449	0.00324	CbGeAlD
Bosutinib—SIK1—bronchus—chronic obstructive pulmonary disease	0.000444	0.0032	CbGeAlD
Bosutinib—IRAK4—bronchus—chronic obstructive pulmonary disease	0.000444	0.0032	CbGeAlD
Bosutinib—CSK—trachea—chronic obstructive pulmonary disease	0.00044	0.00317	CbGeAlD
Bosutinib—EPHA4—bronchus—chronic obstructive pulmonary disease	0.00044	0.00317	CbGeAlD
Bosutinib—CSNK1A1—trachea—chronic obstructive pulmonary disease	0.000437	0.00315	CbGeAlD
Bosutinib—STK25—lung—chronic obstructive pulmonary disease	0.000435	0.00314	CbGeAlD
Bosutinib—RPS6KB1—connective tissue—chronic obstructive pulmonary disease	0.000435	0.00313	CbGeAlD
Bosutinib—HCK—trachea—chronic obstructive pulmonary disease	0.000435	0.00313	CbGeAlD
Bosutinib—CLK1—trachea—chronic obstructive pulmonary disease	0.000435	0.00313	CbGeAlD
Bosutinib—MAP2K2—bronchus—chronic obstructive pulmonary disease	0.000435	0.00313	CbGeAlD
Bosutinib—ULK3—bronchus—chronic obstructive pulmonary disease	0.000435	0.00313	CbGeAlD
Bosutinib—EPHA3—lung—chronic obstructive pulmonary disease	0.000432	0.00311	CbGeAlD
Bosutinib—AXL—connective tissue—chronic obstructive pulmonary disease	0.00043	0.0031	CbGeAlD
Bosutinib—MAP3K7—bronchus—chronic obstructive pulmonary disease	0.000427	0.00308	CbGeAlD
Bosutinib—MAP2K2—smooth muscle tissue—chronic obstructive pulmonary disease	0.000425	0.00307	CbGeAlD
Bosutinib—PLK2—lung—chronic obstructive pulmonary disease	0.000423	0.00305	CbGeAlD
Bosutinib—PTK2—bronchus—chronic obstructive pulmonary disease	0.000422	0.00305	CbGeAlD
Bosutinib—TBK1—bronchus—chronic obstructive pulmonary disease	0.000422	0.00305	CbGeAlD
Bosutinib—SIK3—lung—chronic obstructive pulmonary disease	0.00042	0.00303	CbGeAlD
Bosutinib—MAP3K7—smooth muscle tissue—chronic obstructive pulmonary disease	0.000418	0.00302	CbGeAlD
Bosutinib—IRAK1—bronchus—chronic obstructive pulmonary disease	0.000414	0.00299	CbGeAlD
Bosutinib—PTK2—smooth muscle tissue—chronic obstructive pulmonary disease	0.000413	0.00298	CbGeAlD
Bosutinib—YES1—respiratory system—chronic obstructive pulmonary disease	0.000413	0.00298	CbGeAlD
Bosutinib—EPHB4—connective tissue—chronic obstructive pulmonary disease	0.000411	0.00297	CbGeAlD
Bosutinib—STK10—respiratory system—chronic obstructive pulmonary disease	0.000409	0.00295	CbGeAlD
Bosutinib—TAOK3—respiratory system—chronic obstructive pulmonary disease	0.000408	0.00294	CbGeAlD
Bosutinib—RPS6KB1—bronchus—chronic obstructive pulmonary disease	0.000406	0.00293	CbGeAlD
Bosutinib—CSNK1E—trachea—chronic obstructive pulmonary disease	0.000405	0.00292	CbGeAlD
Bosutinib—IRAK1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000405	0.00292	CbGeAlD
Bosutinib—STK4—lung—chronic obstructive pulmonary disease	0.000404	0.00292	CbGeAlD
Bosutinib—LCK—bronchus—chronic obstructive pulmonary disease	0.000404	0.00291	CbGeAlD
Bosutinib—FYN—connective tissue—chronic obstructive pulmonary disease	0.000403	0.0029	CbGeAlD
Bosutinib—CAMK1D—lung—chronic obstructive pulmonary disease	0.0004	0.00288	CbGeAlD
Bosutinib—IRAK4—trachea—chronic obstructive pulmonary disease	0.000399	0.00288	CbGeAlD
Bosutinib—RPS6KB1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000398	0.00287	CbGeAlD
Bosutinib—SRC—respiratory system—chronic obstructive pulmonary disease	0.000397	0.00286	CbGeAlD
Bosutinib—STK24—lung—chronic obstructive pulmonary disease	0.000395	0.00285	CbGeAlD
Bosutinib—EPHA4—trachea—chronic obstructive pulmonary disease	0.000395	0.00285	CbGeAlD
Bosutinib—AXL—smooth muscle tissue—chronic obstructive pulmonary disease	0.000394	0.00284	CbGeAlD
Bosutinib—ERBB3—trachea—chronic obstructive pulmonary disease	0.000391	0.00282	CbGeAlD
Bosutinib—ULK3—trachea—chronic obstructive pulmonary disease	0.00039	0.00281	CbGeAlD
Bosutinib—SLK—bronchus—chronic obstructive pulmonary disease	0.000387	0.00279	CbGeAlD
Bosutinib—EPHB4—bronchus—chronic obstructive pulmonary disease	0.000385	0.00277	CbGeAlD
Bosutinib—Gefitinib—CYP1A1—chronic obstructive pulmonary disease	0.000384	0.0629	CrCbGaD
Bosutinib—MAP3K7—trachea—chronic obstructive pulmonary disease	0.000384	0.00277	CbGeAlD
Bosutinib—FER—lung—chronic obstructive pulmonary disease	0.000382	0.00276	CbGeAlD
Bosutinib—ALK—lung—chronic obstructive pulmonary disease	0.000382	0.00276	CbGeAlD
Bosutinib—TBK1—trachea—chronic obstructive pulmonary disease	0.000379	0.00274	CbGeAlD
Bosutinib—PTK2—trachea—chronic obstructive pulmonary disease	0.000379	0.00274	CbGeAlD
Bosutinib—EPHA2—bronchus—chronic obstructive pulmonary disease	0.000377	0.00272	CbGeAlD
Bosutinib—FYN—bronchus—chronic obstructive pulmonary disease	0.000377	0.00272	CbGeAlD
Bosutinib—EPHB4—smooth muscle tissue—chronic obstructive pulmonary disease	0.000376	0.00271	CbGeAlD
Bosutinib—MAP4K1—lung—chronic obstructive pulmonary disease	0.000375	0.0027	CbGeAlD
Bosutinib—MAP3K19—lung—chronic obstructive pulmonary disease	0.000375	0.0027	CbGeAlD
Bosutinib—BTK—lung—chronic obstructive pulmonary disease	0.000373	0.00269	CbGeAlD
Bosutinib—Urethral disorder—Arformoterol—chronic obstructive pulmonary disease	0.000369	0.00279	CcSEcCtD
Bosutinib—Urethral disorder—Formoterol—chronic obstructive pulmonary disease	0.000369	0.00279	CcSEcCtD
Bosutinib—FYN—smooth muscle tissue—chronic obstructive pulmonary disease	0.000368	0.00266	CbGeAlD
Bosutinib—Hepatitis—Montelukast—chronic obstructive pulmonary disease	0.000368	0.00278	CcSEcCtD
Bosutinib—MAP4K5—bronchus—chronic obstructive pulmonary disease	0.000368	0.00265	CbGeAlD
Bosutinib—MAP3K3—bronchus—chronic obstructive pulmonary disease	0.000368	0.00265	CbGeAlD
Bosutinib—TNK2—lung—chronic obstructive pulmonary disease	0.000367	0.00265	CbGeAlD
Bosutinib—RPS6KB1—trachea—chronic obstructive pulmonary disease	0.000365	0.00263	CbGeAlD
Bosutinib—Urinary tract disorder—Montelukast—chronic obstructive pulmonary disease	0.000364	0.00275	CcSEcCtD
Bosutinib—YES1—connective tissue—chronic obstructive pulmonary disease	0.000364	0.00262	CbGeAlD
Bosutinib—LCK—trachea—chronic obstructive pulmonary disease	0.000363	0.00262	CbGeAlD
Bosutinib—MAP4K2—lung—chronic obstructive pulmonary disease	0.000362	0.00261	CbGeAlD
Bosutinib—Connective tissue disorder—Montelukast—chronic obstructive pulmonary disease	0.000362	0.00274	CcSEcCtD
Bosutinib—AXL—trachea—chronic obstructive pulmonary disease	0.000361	0.00261	CbGeAlD
Bosutinib—Urethral disorder—Montelukast—chronic obstructive pulmonary disease	0.000361	0.00273	CcSEcCtD
Bosutinib—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00036	0.00272	CcSEcCtD
Bosutinib—MAP4K5—smooth muscle tissue—chronic obstructive pulmonary disease	0.00036	0.0026	CbGeAlD
Bosutinib—TAOK3—connective tissue—chronic obstructive pulmonary disease	0.000359	0.00259	CbGeAlD
Bosutinib—STK3—lung—chronic obstructive pulmonary disease	0.000357	0.00258	CbGeAlD
Bosutinib—ERBB4—lung—chronic obstructive pulmonary disease	0.000357	0.00258	CbGeAlD
Bosutinib—CSF1R—respiratory system—chronic obstructive pulmonary disease	0.000357	0.00257	CbGeAlD
Bosutinib—Cough—Tiotropium—chronic obstructive pulmonary disease	0.000354	0.00268	CcSEcCtD
Bosutinib—ROCK1—lung—chronic obstructive pulmonary disease	0.000353	0.00254	CbGeAlD
Bosutinib—Anaphylactic shock—Aminophylline—chronic obstructive pulmonary disease	0.000351	0.00265	CcSEcCtD
Bosutinib—Urinary tract disorder—Salbutamol—chronic obstructive pulmonary disease	0.000351	0.00265	CcSEcCtD
Bosutinib—Acne—Prednisone—chronic obstructive pulmonary disease	0.00035	0.00265	CcSEcCtD
Bosutinib—SRC—connective tissue—chronic obstructive pulmonary disease	0.00035	0.00252	CbGeAlD
Bosutinib—Cardiac disorder—Formoterol—chronic obstructive pulmonary disease	0.000349	0.00264	CcSEcCtD
Bosutinib—Cardiac disorder—Arformoterol—chronic obstructive pulmonary disease	0.000349	0.00264	CcSEcCtD
Bosutinib—Connective tissue disorder—Salbutamol—chronic obstructive pulmonary disease	0.000349	0.00264	CcSEcCtD
Bosutinib—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000349	0.00264	CcSEcCtD
Bosutinib—Erythema multiforme—Montelukast—chronic obstructive pulmonary disease	0.000348	0.00263	CcSEcCtD
Bosutinib—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000348	0.00263	CcSEcCtD
Bosutinib—Urethral disorder—Salbutamol—chronic obstructive pulmonary disease	0.000348	0.00263	CcSEcCtD
Bosutinib—SLK—trachea—chronic obstructive pulmonary disease	0.000348	0.00251	CbGeAlD
Bosutinib—EPHB4—trachea—chronic obstructive pulmonary disease	0.000345	0.00249	CbGeAlD
Bosutinib—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.000345	0.00261	CcSEcCtD
Bosutinib—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.000345	0.00261	CcSEcCtD
Bosutinib—Chest pain—Tiotropium—chronic obstructive pulmonary disease	0.000345	0.00261	CcSEcCtD
Bosutinib—Nervous system disorder—Aminophylline—chronic obstructive pulmonary disease	0.000344	0.0026	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Tiotropium—chronic obstructive pulmonary disease	0.000343	0.00259	CcSEcCtD
Bosutinib—BMPR2—lung—chronic obstructive pulmonary disease	0.000343	0.00247	CbGeAlD
Bosutinib—Cardiac disorder—Montelukast—chronic obstructive pulmonary disease	0.000342	0.00258	CcSEcCtD
Bosutinib—YES1—bronchus—chronic obstructive pulmonary disease	0.00034	0.00245	CbGeAlD
Bosutinib—EPHB3—lung—chronic obstructive pulmonary disease	0.00034	0.00245	CbGeAlD
Bosutinib—STK36—lung—chronic obstructive pulmonary disease	0.00034	0.00245	CbGeAlD
Bosutinib—Immune system disorder—Formoterol—chronic obstructive pulmonary disease	0.00034	0.00257	CcSEcCtD
Bosutinib—Immune system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00034	0.00257	CcSEcCtD
Bosutinib—Mediastinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000339	0.00256	CcSEcCtD
Bosutinib—Mediastinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000339	0.00256	CcSEcCtD
Bosutinib—EPHA2—trachea—chronic obstructive pulmonary disease	0.000339	0.00244	CbGeAlD
Bosutinib—FYN—trachea—chronic obstructive pulmonary disease	0.000338	0.00244	CbGeAlD
Bosutinib—STK10—bronchus—chronic obstructive pulmonary disease	0.000337	0.00243	CbGeAlD
Bosutinib—MERTK—lung—chronic obstructive pulmonary disease	0.000336	0.00242	CbGeAlD
Bosutinib—TAOK3—bronchus—chronic obstructive pulmonary disease	0.000335	0.00242	CbGeAlD
Bosutinib—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000335	0.00253	CcSEcCtD
Bosutinib—Immune system disorder—Montelukast—chronic obstructive pulmonary disease	0.000333	0.00251	CcSEcCtD
Bosutinib—YES1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000333	0.0024	CbGeAlD
Bosutinib—Mediastinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000332	0.00251	CcSEcCtD
Bosutinib—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000332	0.00251	CcSEcCtD
Bosutinib—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000332	0.00251	CcSEcCtD
Bosutinib—Tinnitus—Salbutamol—chronic obstructive pulmonary disease	0.000331	0.0025	CcSEcCtD
Bosutinib—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.000331	0.0025	CcSEcCtD
Bosutinib—MAP4K5—trachea—chronic obstructive pulmonary disease	0.00033	0.00238	CbGeAlD
Bosutinib—MAP3K3—trachea—chronic obstructive pulmonary disease	0.00033	0.00238	CbGeAlD
Bosutinib—MAP4K4—lung—chronic obstructive pulmonary disease	0.00033	0.00238	CbGeAlD
Bosutinib—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00033	0.00249	CcSEcCtD
Bosutinib—Cardiac disorder—Salbutamol—chronic obstructive pulmonary disease	0.000329	0.00249	CcSEcCtD
Bosutinib—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000329	0.00249	CcSEcCtD
Bosutinib—NUAK2—lung—chronic obstructive pulmonary disease	0.000327	0.00236	CbGeAlD
Bosutinib—BCR—lung—chronic obstructive pulmonary disease	0.000327	0.00236	CbGeAlD
Bosutinib—Malnutrition—Arformoterol—chronic obstructive pulmonary disease	0.000327	0.00247	CcSEcCtD
Bosutinib—Malnutrition—Formoterol—chronic obstructive pulmonary disease	0.000327	0.00247	CcSEcCtD
Bosutinib—MAP3K12—lung—chronic obstructive pulmonary disease	0.000325	0.00234	CbGeAlD
Bosutinib—Nervous system disorder—Tiotropium—chronic obstructive pulmonary disease	0.000325	0.00245	CcSEcCtD
Bosutinib—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000321	0.00243	CcSEcCtD
Bosutinib—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000321	0.00242	CcSEcCtD
Bosutinib—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.00032	0.00242	CcSEcCtD
Bosutinib—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.00032	0.00242	CcSEcCtD
Bosutinib—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00032	0.00242	CcSEcCtD
Bosutinib—SRC—smooth muscle tissue—chronic obstructive pulmonary disease	0.00032	0.00231	CbGeAlD
Bosutinib—MAP2K1—lung—chronic obstructive pulmonary disease	0.000318	0.0023	CbGeAlD
Bosutinib—STK35—lung—chronic obstructive pulmonary disease	0.000318	0.0023	CbGeAlD
Bosutinib—Back pain—Arformoterol—chronic obstructive pulmonary disease	0.000317	0.00239	CcSEcCtD
Bosutinib—Back pain—Formoterol—chronic obstructive pulmonary disease	0.000317	0.00239	CcSEcCtD
Bosutinib—CSK—lung—chronic obstructive pulmonary disease	0.000316	0.00228	CbGeAlD
Bosutinib—PDGFRB—respiratory system—chronic obstructive pulmonary disease	0.000316	0.00228	CbGeAlD
Bosutinib—CSNK1A1—lung—chronic obstructive pulmonary disease	0.000314	0.00227	CbGeAlD
Bosutinib—CSF1R—connective tissue—chronic obstructive pulmonary disease	0.000314	0.00226	CbGeAlD
Bosutinib—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000313	0.00236	CcSEcCtD
Bosutinib—HCK—lung—chronic obstructive pulmonary disease	0.000312	0.00225	CbGeAlD
Bosutinib—CLK1—lung—chronic obstructive pulmonary disease	0.000312	0.00225	CbGeAlD
Bosutinib—ABL2—lung—chronic obstructive pulmonary disease	0.00031	0.00224	CbGeAlD
Bosutinib—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	0.000309	0.00234	CcSEcCtD
Bosutinib—BMP2K—lung—chronic obstructive pulmonary disease	0.000307	0.00221	CbGeAlD
Bosutinib—CAMK2G—lung—chronic obstructive pulmonary disease	0.000307	0.00221	CbGeAlD
Bosutinib—YES1—trachea—chronic obstructive pulmonary disease	0.000305	0.0022	CbGeAlD
Bosutinib—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000305	0.00231	CcSEcCtD
Bosutinib—LRRK2—lung—chronic obstructive pulmonary disease	0.000304	0.00219	CbGeAlD
Bosutinib—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000304	0.0023	CcSEcCtD
Bosutinib—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000304	0.0023	CcSEcCtD
Bosutinib—EGFR—lung—chronic obstructive pulmonary disease	0.000303	0.00218	CbGeAlD
Bosutinib—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000303	0.00229	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000302	0.00228	CcSEcCtD
Bosutinib—TAOK3—trachea—chronic obstructive pulmonary disease	0.000301	0.00217	CbGeAlD
Bosutinib—MAP2K5—bronchus—chronic obstructive pulmonary disease	0.000301	0.00217	CbGeAlD
Bosutinib—Back pain—Salbutamol—chronic obstructive pulmonary disease	0.000299	0.00226	CcSEcCtD
Bosutinib—PTK2B—lung—chronic obstructive pulmonary disease	0.000296	0.00213	CbGeAlD
Bosutinib—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000295	0.00223	CcSEcCtD
Bosutinib—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000295	0.00223	CcSEcCtD
Bosutinib—CSF1R—bronchus—chronic obstructive pulmonary disease	0.000294	0.00212	CbGeAlD
Bosutinib—CSNK1E—lung—chronic obstructive pulmonary disease	0.000291	0.0021	CbGeAlD
Bosutinib—CSF1R—smooth muscle tissue—chronic obstructive pulmonary disease	0.000287	0.00207	CbGeAlD
Bosutinib—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000287	0.00217	CcSEcCtD
Bosutinib—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000287	0.00217	CcSEcCtD
Bosutinib—SIK1—lung—chronic obstructive pulmonary disease	0.000287	0.00207	CbGeAlD
Bosutinib—IRAK4—lung—chronic obstructive pulmonary disease	0.000287	0.00207	CbGeAlD
Bosutinib—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000286	0.00216	CcSEcCtD
Bosutinib—Cough—Formoterol—chronic obstructive pulmonary disease	0.000286	0.00216	CcSEcCtD
Bosutinib—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000286	0.00216	CcSEcCtD
Bosutinib—EPHA4—lung—chronic obstructive pulmonary disease	0.000284	0.00205	CbGeAlD
Bosutinib—ABL1—respiratory system—chronic obstructive pulmonary disease	0.000282	0.00203	CbGeAlD
Bosutinib—ERBB3—lung—chronic obstructive pulmonary disease	0.000281	0.00203	CbGeAlD
Bosutinib—MAP2K2—lung—chronic obstructive pulmonary disease	0.00028	0.00202	CbGeAlD
Bosutinib—ULK3—lung—chronic obstructive pulmonary disease	0.00028	0.00202	CbGeAlD
Bosutinib—PKMYT1—Danazol—Prednisone—chronic obstructive pulmonary disease	0.00028	0.12	CbGdCrCtD
Bosutinib—Cough—Montelukast—chronic obstructive pulmonary disease	0.00028	0.00211	CcSEcCtD
Bosutinib—Fluid retention—Prednisone—chronic obstructive pulmonary disease	0.00028	0.00211	CcSEcCtD
Bosutinib—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000279	0.00211	CcSEcCtD
Bosutinib—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000279	0.00211	CcSEcCtD
Bosutinib—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000279	0.00211	CcSEcCtD
Bosutinib—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000279	0.00211	CcSEcCtD
Bosutinib—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000279	0.00211	CcSEcCtD
Bosutinib—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000279	0.00211	CcSEcCtD
Bosutinib—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000279	0.00211	CcSEcCtD
Bosutinib—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000279	0.00211	CcSEcCtD
Bosutinib—PDGFRB—connective tissue—chronic obstructive pulmonary disease	0.000278	0.00201	CbGeAlD
Bosutinib—MAP3K2—lung—chronic obstructive pulmonary disease	0.000278	0.00201	CbGeAlD
Bosutinib—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000277	0.0021	CcSEcCtD
Bosutinib—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000277	0.0021	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.000277	0.00209	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.000277	0.00209	CcSEcCtD
Bosutinib—MAP3K7—lung—chronic obstructive pulmonary disease	0.000276	0.00199	CbGeAlD
Bosutinib—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000275	0.00208	CcSEcCtD
Bosutinib—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000275	0.00208	CcSEcCtD
Bosutinib—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000273	0.00206	CcSEcCtD
Bosutinib—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000273	0.00206	CcSEcCtD
Bosutinib—PTK2—lung—chronic obstructive pulmonary disease	0.000273	0.00197	CbGeAlD
Bosutinib—TBK1—lung—chronic obstructive pulmonary disease	0.000273	0.00197	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000271	0.00205	CcSEcCtD
Bosutinib—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000271	0.00205	CcSEcCtD
Bosutinib—MAP2K5—trachea—chronic obstructive pulmonary disease	0.00027	0.00195	CbGeAlD
Bosutinib—Cough—Salbutamol—chronic obstructive pulmonary disease	0.00027	0.00204	CcSEcCtD
Bosutinib—IRAK1—lung—chronic obstructive pulmonary disease	0.000267	0.00193	CbGeAlD
Bosutinib—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000267	0.00202	CcSEcCtD
Bosutinib—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000267	0.00202	CcSEcCtD
Bosutinib—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000267	0.00202	CcSEcCtD
Bosutinib—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000267	0.00202	CcSEcCtD
Bosutinib—CSNK1E—Danazol—Prednisone—chronic obstructive pulmonary disease	0.000267	0.115	CbGdCrCtD
Bosutinib—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000265	0.00201	CcSEcCtD
Bosutinib—Infection—Formoterol—chronic obstructive pulmonary disease	0.000265	0.00201	CcSEcCtD
Bosutinib—CSF1R—trachea—chronic obstructive pulmonary disease	0.000264	0.0019	CbGeAlD
Bosutinib—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000263	0.00199	CcSEcCtD
Bosutinib—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000263	0.00199	CcSEcCtD
Bosutinib—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000263	0.00199	CcSEcCtD
Bosutinib—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000263	0.00199	CcSEcCtD
Bosutinib—RPS6KB1—lung—chronic obstructive pulmonary disease	0.000262	0.00189	CbGeAlD
Bosutinib—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000262	0.00198	CcSEcCtD
Bosutinib—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000262	0.00198	CcSEcCtD
Bosutinib—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000262	0.00198	CcSEcCtD
Bosutinib—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000262	0.00198	CcSEcCtD
Bosutinib—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000262	0.00198	CcSEcCtD
Bosutinib—FGR—lung—chronic obstructive pulmonary disease	0.000261	0.00188	CbGeAlD
Bosutinib—LCK—lung—chronic obstructive pulmonary disease	0.000261	0.00188	CbGeAlD
Bosutinib—PDGFRB—bronchus—chronic obstructive pulmonary disease	0.00026	0.00188	CbGeAlD
Bosutinib—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00026	0.00197	CcSEcCtD
Bosutinib—Infection—Montelukast—chronic obstructive pulmonary disease	0.00026	0.00196	CcSEcCtD
Bosutinib—AXL—lung—chronic obstructive pulmonary disease	0.00026	0.00187	CbGeAlD
Bosutinib—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000259	0.00196	CcSEcCtD
Bosutinib—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000259	0.00196	CcSEcCtD
Bosutinib—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000257	0.00194	CcSEcCtD
Bosutinib—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000256	0.00194	CcSEcCtD
Bosutinib—PDGFRB—smooth muscle tissue—chronic obstructive pulmonary disease	0.000255	0.00184	CbGeAlD
Bosutinib—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000254	0.00192	CcSEcCtD
Bosutinib—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000252	0.00191	CcSEcCtD
Bosutinib—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000252	0.00191	CcSEcCtD
Bosutinib—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000251	0.00189	CcSEcCtD
Bosutinib—SLK—lung—chronic obstructive pulmonary disease	0.00025	0.0018	CbGeAlD
Bosutinib—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000248	0.00188	CcSEcCtD
Bosutinib—ABL1—connective tissue—chronic obstructive pulmonary disease	0.000248	0.00179	CbGeAlD
Bosutinib—EPHB4—lung—chronic obstructive pulmonary disease	0.000248	0.00179	CbGeAlD
Bosutinib—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000247	0.00187	CcSEcCtD
Bosutinib—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000245	0.00185	CcSEcCtD
Bosutinib—EPHA2—lung—chronic obstructive pulmonary disease	0.000243	0.00175	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000243	0.00184	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000243	0.00184	CcSEcCtD
Bosutinib—FYN—lung—chronic obstructive pulmonary disease	0.000243	0.00175	CbGeAlD
Bosutinib—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00024	0.00182	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000238	0.0018	CcSEcCtD
Bosutinib—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000238	0.0018	CcSEcCtD
Bosutinib—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000238	0.0018	CcSEcCtD
Bosutinib—MAP4K5—lung—chronic obstructive pulmonary disease	0.000237	0.00171	CbGeAlD
Bosutinib—MAP3K3—lung—chronic obstructive pulmonary disease	0.000237	0.00171	CbGeAlD
Bosutinib—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000234	0.00177	CcSEcCtD
Bosutinib—PDGFRB—trachea—chronic obstructive pulmonary disease	0.000234	0.00169	CbGeAlD
Bosutinib—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000232	0.00175	CcSEcCtD
Bosutinib—ABL1—bronchus—chronic obstructive pulmonary disease	0.000232	0.00167	CbGeAlD
Bosutinib—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000231	0.00174	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000231	0.00174	CcSEcCtD
Bosutinib—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.00023	0.00174	CcSEcCtD
Bosutinib—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.00023	0.00174	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00023	0.00174	CcSEcCtD
Bosutinib—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000228	0.00173	CcSEcCtD
Bosutinib—Pain—Formoterol—chronic obstructive pulmonary disease	0.000228	0.00173	CcSEcCtD
Bosutinib—ABL1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000227	0.00164	CbGeAlD
Bosutinib—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000226	0.00171	CcSEcCtD
Bosutinib—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000226	0.00171	CcSEcCtD
Bosutinib—Vandetanib—ALB—chronic obstructive pulmonary disease	0.000225	0.0368	CrCbGaD
Bosutinib—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000225	0.0017	CcSEcCtD
Bosutinib—Pain—Montelukast—chronic obstructive pulmonary disease	0.000224	0.00169	CcSEcCtD
Bosutinib—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000223	0.00169	CcSEcCtD
Bosutinib—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000221	0.00167	CcSEcCtD
Bosutinib—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000221	0.00167	CcSEcCtD
Bosutinib—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.00022	0.00166	CcSEcCtD
Bosutinib—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.00022	0.00166	CcSEcCtD
Bosutinib—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00022	0.00166	CcSEcCtD
Bosutinib—YES1—lung—chronic obstructive pulmonary disease	0.000219	0.00158	CbGeAlD
Bosutinib—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000219	0.00166	CcSEcCtD
Bosutinib—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000219	0.00165	CcSEcCtD
Bosutinib—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000218	0.00165	CcSEcCtD
Bosutinib—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000218	0.00165	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000218	0.00165	CcSEcCtD
Bosutinib—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000217	0.00164	CcSEcCtD
Bosutinib—STK10—lung—chronic obstructive pulmonary disease	0.000217	0.00157	CbGeAlD
Bosutinib—TAOK3—lung—chronic obstructive pulmonary disease	0.000216	0.00156	CbGeAlD
Bosutinib—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000216	0.00163	CcSEcCtD
Bosutinib—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000214	0.00162	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000214	0.00162	CcSEcCtD
Bosutinib—Gefitinib—ALB—chronic obstructive pulmonary disease	0.000214	0.035	CrCbGaD
Bosutinib—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000212	0.0016	CcSEcCtD
Bosutinib—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000212	0.0016	CcSEcCtD
Bosutinib—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000211	0.0016	CcSEcCtD
Bosutinib—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000211	0.0016	CcSEcCtD
Bosutinib—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000211	0.0016	CcSEcCtD
Bosutinib—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000211	0.0016	CcSEcCtD
Bosutinib—SRC—lung—chronic obstructive pulmonary disease	0.000211	0.00152	CbGeAlD
Bosutinib—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00021	0.00159	CcSEcCtD
Bosutinib—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000209	0.00158	CcSEcCtD
Bosutinib—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000208	0.00158	CcSEcCtD
Bosutinib—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000208	0.00158	CcSEcCtD
Bosutinib—ABL1—trachea—chronic obstructive pulmonary disease	0.000208	0.0015	CbGeAlD
Bosutinib—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000208	0.00157	CcSEcCtD
Bosutinib—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000208	0.00157	CcSEcCtD
Bosutinib—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000207	0.00157	CcSEcCtD
Bosutinib—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000207	0.00156	CcSEcCtD
Bosutinib—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000207	0.00156	CcSEcCtD
Bosutinib—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000206	0.00156	CcSEcCtD
Bosutinib—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000206	0.00156	CcSEcCtD
Bosutinib—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.0002	0.00151	CcSEcCtD
Bosutinib—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000199	0.00151	CcSEcCtD
Bosutinib—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000199	0.00151	CcSEcCtD
Bosutinib—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000197	0.00149	CcSEcCtD
Bosutinib—MAP2K5—lung—chronic obstructive pulmonary disease	0.000194	0.0014	CbGeAlD
Bosutinib—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000192	0.00145	CcSEcCtD
Bosutinib—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000192	0.00145	CcSEcCtD
Bosutinib—CSF1R—lung—chronic obstructive pulmonary disease	0.000189	0.00137	CbGeAlD
Bosutinib—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000189	0.00143	CcSEcCtD
Bosutinib—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000189	0.00143	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000189	0.00143	CcSEcCtD
Bosutinib—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000188	0.00142	CcSEcCtD
Bosutinib—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000185	0.0014	CcSEcCtD
Bosutinib—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000183	0.00138	CcSEcCtD
Bosutinib—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000183	0.00138	CcSEcCtD
Bosutinib—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000181	0.00137	CcSEcCtD
Bosutinib—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000179	0.00135	CcSEcCtD
Bosutinib—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000178	0.00135	CcSEcCtD
Bosutinib—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000177	0.00134	CcSEcCtD
Bosutinib—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000177	0.00134	CcSEcCtD
Bosutinib—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000173	0.00131	CcSEcCtD
Bosutinib—Neutropenia—Prednisone—chronic obstructive pulmonary disease	0.000173	0.00131	CcSEcCtD
Bosutinib—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000173	0.0013	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Prednisone—chronic obstructive pulmonary disease	0.00017	0.0731	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisone—chronic obstructive pulmonary disease	0.00017	0.0731	CbGdCrCtD
Bosutinib—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.00017	0.00128	CcSEcCtD
Bosutinib—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.00128	CcSEcCtD
Bosutinib—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000168	0.00127	CcSEcCtD
Bosutinib—Rash—Formoterol—chronic obstructive pulmonary disease	0.000168	0.00127	CcSEcCtD
Bosutinib—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000168	0.00127	CcSEcCtD
Bosutinib—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000168	0.00127	CcSEcCtD
Bosutinib—PDGFRB—lung—chronic obstructive pulmonary disease	0.000168	0.00121	CbGeAlD
Bosutinib—Headache—Formoterol—chronic obstructive pulmonary disease	0.000167	0.00127	CcSEcCtD
Bosutinib—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000167	0.00127	CcSEcCtD
Bosutinib—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000167	0.00126	CcSEcCtD
Bosutinib—CSNK1E—Betamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000166	0.0713	CbGdCrCtD
Bosutinib—CSNK1E—Dexamethasone—Prednisolone—chronic obstructive pulmonary disease	0.000166	0.0713	CbGdCrCtD
Bosutinib—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000166	0.00126	CcSEcCtD
Bosutinib—Rash—Montelukast—chronic obstructive pulmonary disease	0.000165	0.00125	CcSEcCtD
Bosutinib—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000165	0.00125	CcSEcCtD
Bosutinib—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000164	0.00124	CcSEcCtD
Bosutinib—Headache—Montelukast—chronic obstructive pulmonary disease	0.000164	0.00124	CcSEcCtD
Bosutinib—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00016	0.00121	CcSEcCtD
Bosutinib—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.00016	0.00121	CcSEcCtD
Bosutinib—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.0012	CcSEcCtD
Bosutinib—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000159	0.0012	CcSEcCtD
Bosutinib—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000159	0.0012	CcSEcCtD
Bosutinib—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000159	0.0012	CcSEcCtD
Bosutinib—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000158	0.00119	CcSEcCtD
Bosutinib—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000155	0.00117	CcSEcCtD
Bosutinib—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00015	0.00113	CcSEcCtD
Bosutinib—ABL1—lung—chronic obstructive pulmonary disease	0.00015	0.00108	CbGeAlD
Bosutinib—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000149	0.00113	CcSEcCtD
Bosutinib—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000145	0.0011	CcSEcCtD
Bosutinib—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000145	0.00109	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000145	0.00109	CcSEcCtD
Bosutinib—CHEK2—Danazol—Prednisone—chronic obstructive pulmonary disease	0.000137	0.0586	CbGdCrCtD
Bosutinib—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000134	0.00101	CcSEcCtD
Bosutinib—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000974	CcSEcCtD
Bosutinib—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000124	0.000935	CcSEcCtD
Bosutinib—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000903	CcSEcCtD
Bosutinib—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000119	0.000901	CcSEcCtD
Bosutinib—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000119	0.0009	CcSEcCtD
Bosutinib—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000116	0.000878	CcSEcCtD
Bosutinib—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000115	0.000869	CcSEcCtD
Bosutinib—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000829	CcSEcCtD
Bosutinib—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000829	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000109	0.000823	CcSEcCtD
Bosutinib—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000819	CcSEcCtD
Bosutinib—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000795	CcSEcCtD
Bosutinib—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000795	CcSEcCtD
Bosutinib—Infection—Prednisone—chronic obstructive pulmonary disease	0.000104	0.000789	CcSEcCtD
Bosutinib—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000779	CcSEcCtD
Bosutinib—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000772	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	9.58e-05	0.000724	CcSEcCtD
Bosutinib—Dizziness—Prednisolone—chronic obstructive pulmonary disease	9.57e-05	0.000723	CcSEcCtD
Bosutinib—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	9.14e-05	0.000691	CcSEcCtD
Bosutinib—Rash—Prednisolone—chronic obstructive pulmonary disease	9.12e-05	0.00069	CcSEcCtD
Bosutinib—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	9.11e-05	0.000689	CcSEcCtD
Bosutinib—Fatigue—Prednisone—chronic obstructive pulmonary disease	9.06e-05	0.000685	CcSEcCtD
Bosutinib—Headache—Prednisolone—chronic obstructive pulmonary disease	9.06e-05	0.000685	CcSEcCtD
Bosutinib—ABCB1—respiratory system—chronic obstructive pulmonary disease	8.77e-05	0.000632	CbGeAlD
Bosutinib—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	8.66e-05	0.000655	CcSEcCtD
Bosutinib—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	8.6e-05	0.00065	CcSEcCtD
Bosutinib—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.59e-05	0.00065	CcSEcCtD
Bosutinib—Urticaria—Prednisone—chronic obstructive pulmonary disease	8.35e-05	0.000631	CcSEcCtD
Bosutinib—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	8.31e-05	0.000628	CcSEcCtD
Bosutinib—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	8.31e-05	0.000628	CcSEcCtD
Bosutinib—Asthenia—Prednisone—chronic obstructive pulmonary disease	7.54e-05	0.00057	CcSEcCtD
Bosutinib—Pruritus—Prednisone—chronic obstructive pulmonary disease	7.44e-05	0.000562	CcSEcCtD
Bosutinib—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	7.19e-05	0.000544	CcSEcCtD
Bosutinib—Dizziness—Prednisone—chronic obstructive pulmonary disease	6.95e-05	0.000526	CcSEcCtD
Bosutinib—Vomiting—Prednisone—chronic obstructive pulmonary disease	6.68e-05	0.000505	CcSEcCtD
Bosutinib—Rash—Prednisone—chronic obstructive pulmonary disease	6.63e-05	0.000501	CcSEcCtD
Bosutinib—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.62e-05	0.000501	CcSEcCtD
Bosutinib—Headache—Prednisone—chronic obstructive pulmonary disease	6.58e-05	0.000498	CcSEcCtD
Bosutinib—ABCB1—trachea—chronic obstructive pulmonary disease	6.48e-05	0.000467	CbGeAlD
Bosutinib—Nausea—Prednisone—chronic obstructive pulmonary disease	6.24e-05	0.000472	CcSEcCtD
Bosutinib—ABCB1—lung—chronic obstructive pulmonary disease	4.65e-05	0.000336	CbGeAlD
Bosutinib—MAP2K1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.97e-06	1.74e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.96e-06	1.74e-05	CbGpPWpGaD
Bosutinib—FYN—Innate Immune System—IL6—chronic obstructive pulmonary disease	2.96e-06	1.73e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.95e-06	1.73e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL1B—chronic obstructive pulmonary disease	2.94e-06	1.72e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Innate Immune System—IL6—chronic obstructive pulmonary disease	2.94e-06	1.72e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GCLC—chronic obstructive pulmonary disease	2.93e-06	1.72e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—NOS2—chronic obstructive pulmonary disease	2.92e-06	1.71e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL1B—chronic obstructive pulmonary disease	2.92e-06	1.71e-05	CbGpPWpGaD
Bosutinib—BLK—Immune System—IL6—chronic obstructive pulmonary disease	2.91e-06	1.71e-05	CbGpPWpGaD
Bosutinib—FGR—Immune System—IL6—chronic obstructive pulmonary disease	2.9e-06	1.7e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	2.9e-06	1.7e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—EGFR—chronic obstructive pulmonary disease	2.89e-06	1.7e-05	CbGpPWpGaD
Bosutinib—EGFR—Developmental Biology—IL6—chronic obstructive pulmonary disease	2.89e-06	1.7e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—SERPINE1—chronic obstructive pulmonary disease	2.89e-06	1.69e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.89e-06	1.69e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.88e-06	1.69e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.88e-06	1.69e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.88e-06	1.69e-05	CbGpPWpGaD
Bosutinib—SYK—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.86e-06	1.68e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.85e-06	1.67e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—EGFR—chronic obstructive pulmonary disease	2.83e-06	1.66e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.83e-06	1.66e-05	CbGpPWpGaD
Bosutinib—PRKCQ—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.81e-06	1.65e-05	CbGpPWpGaD
Bosutinib—CSNK1A1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.81e-06	1.65e-05	CbGpPWpGaD
Bosutinib—ERBB4—Disease—IL6—chronic obstructive pulmonary disease	2.8e-06	1.64e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.79e-06	1.64e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—SERPINE1—chronic obstructive pulmonary disease	2.78e-06	1.63e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.78e-06	1.63e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.77e-06	1.63e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.77e-06	1.62e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—NOS3—chronic obstructive pulmonary disease	2.76e-06	1.62e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.74e-06	1.6e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—EGFR—chronic obstructive pulmonary disease	2.72e-06	1.6e-05	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	2.72e-06	1.6e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.72e-06	1.59e-05	CbGpPWpGaD
Bosutinib—CSK—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.71e-06	1.59e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	2.7e-06	1.58e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.7e-06	1.58e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.69e-06	1.58e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CTGF—chronic obstructive pulmonary disease	2.68e-06	1.57e-05	CbGpPWpGaD
Bosutinib—ERBB3—Immune System—IL6—chronic obstructive pulmonary disease	2.67e-06	1.57e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.67e-06	1.57e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—NOS3—chronic obstructive pulmonary disease	2.66e-06	1.56e-05	CbGpPWpGaD
Bosutinib—SRC—Hemostasis—TP53—chronic obstructive pulmonary disease	2.64e-06	1.55e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.61e-06	1.53e-05	CbGpPWpGaD
Bosutinib—ABCB1—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.6e-06	1.52e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.6e-06	1.52e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.59e-06	1.52e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.59e-06	1.52e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.58e-06	1.51e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.56e-06	1.5e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.56e-06	1.5e-05	CbGpPWpGaD
Bosutinib—EGFR—Innate Immune System—IL6—chronic obstructive pulmonary disease	2.55e-06	1.5e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.55e-06	1.49e-05	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL1B—chronic obstructive pulmonary disease	2.54e-06	1.49e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.51e-06	1.47e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.5e-06	1.46e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.49e-06	1.46e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.48e-06	1.46e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.48e-06	1.45e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.48e-06	1.45e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.47e-06	1.45e-05	CbGpPWpGaD
Bosutinib—SRC—Developmental Biology—IL6—chronic obstructive pulmonary disease	2.47e-06	1.45e-05	CbGpPWpGaD
Bosutinib—ERBB3—Disease—IL6—chronic obstructive pulmonary disease	2.47e-06	1.45e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.47e-06	1.45e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—SERPINE1—chronic obstructive pulmonary disease	2.46e-06	1.44e-05	CbGpPWpGaD
Bosutinib—LCK—Innate Immune System—IL6—chronic obstructive pulmonary disease	2.46e-06	1.44e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	2.46e-06	1.44e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL1B—chronic obstructive pulmonary disease	2.45e-06	1.43e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.44e-06	1.43e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.44e-06	1.43e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.43e-06	1.42e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.42e-06	1.42e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.41e-06	1.41e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—EGFR—chronic obstructive pulmonary disease	2.38e-06	1.4e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.38e-06	1.39e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.38e-06	1.39e-05	CbGpPWpGaD
Bosutinib—PTK2—Immune System—IL6—chronic obstructive pulmonary disease	2.38e-06	1.39e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.38e-06	1.39e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.37e-06	1.39e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	2.36e-06	1.39e-05	CbGpPWpGaD
Bosutinib—SRC—Disease—NOS3—chronic obstructive pulmonary disease	2.35e-06	1.38e-05	CbGpPWpGaD
Bosutinib—YES1—Immune System—IL6—chronic obstructive pulmonary disease	2.34e-06	1.37e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.34e-06	1.37e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.33e-06	1.37e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.33e-06	1.37e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.33e-06	1.36e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—EGFR—chronic obstructive pulmonary disease	2.32e-06	1.36e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.32e-06	1.36e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.32e-06	1.36e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.29e-06	1.34e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—EGFR—chronic obstructive pulmonary disease	2.27e-06	1.33e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.27e-06	1.33e-05	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.27e-06	1.33e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—EGFR—chronic obstructive pulmonary disease	2.26e-06	1.33e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.25e-06	1.32e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—TGFB1—chronic obstructive pulmonary disease	2.24e-06	1.31e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—EGFR—chronic obstructive pulmonary disease	2.24e-06	1.31e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.23e-06	1.31e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—EGFR—chronic obstructive pulmonary disease	2.23e-06	1.31e-05	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—IL6—chronic obstructive pulmonary disease	2.22e-06	1.3e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.22e-06	1.3e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.22e-06	1.3e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—EGFR—chronic obstructive pulmonary disease	2.2e-06	1.29e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—LEP—chronic obstructive pulmonary disease	2.2e-06	1.29e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.19e-06	1.29e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—TGFB1—chronic obstructive pulmonary disease	2.19e-06	1.28e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.18e-06	1.28e-05	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—IL6—chronic obstructive pulmonary disease	2.18e-06	1.28e-05	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL1B—chronic obstructive pulmonary disease	2.17e-06	1.27e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—EGFR—chronic obstructive pulmonary disease	2.15e-06	1.26e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.14e-06	1.25e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.11e-06	1.24e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—TGFB1—chronic obstructive pulmonary disease	2.11e-06	1.24e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.11e-06	1.23e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—TGFB1—chronic obstructive pulmonary disease	2.1e-06	1.23e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL6—chronic obstructive pulmonary disease	2.09e-06	1.23e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.08e-06	1.22e-05	CbGpPWpGaD
Bosutinib—FYN—Disease—EGFR—chronic obstructive pulmonary disease	2.07e-06	1.21e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EGFR—chronic obstructive pulmonary disease	2.06e-06	1.21e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.06e-06	1.21e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.06e-06	1.21e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.04e-06	1.2e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.03e-06	1.19e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.03e-06	1.19e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.02e-06	1.19e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.01e-06	1.18e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.01e-06	1.18e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2e-06	1.17e-05	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2e-06	1.17e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.98e-06	1.16e-05	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.97e-06	1.16e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.97e-06	1.16e-05	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.96e-06	1.15e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.96e-06	1.15e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.96e-06	1.15e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.96e-06	1.15e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.95e-06	1.14e-05	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.93e-06	1.13e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.93e-06	1.13e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.91e-06	1.12e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.9e-06	1.12e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.89e-06	1.11e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.89e-06	1.11e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.87e-06	1.1e-05	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.87e-06	1.1e-05	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—chronic obstructive pulmonary disease	1.86e-06	1.09e-05	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.86e-06	1.09e-05	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.86e-06	1.09e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.86e-06	1.09e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—chronic obstructive pulmonary disease	1.83e-06	1.07e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.83e-06	1.07e-05	CbGpPWpGaD
Bosutinib—EGFR—Disease—TGFB1—chronic obstructive pulmonary disease	1.82e-06	1.07e-05	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.82e-06	1.07e-05	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.81e-06	1.06e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.8e-06	1.05e-05	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.79e-06	1.05e-05	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.79e-06	1.05e-05	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.79e-06	1.05e-05	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.79e-06	1.05e-05	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—chronic obstructive pulmonary disease	1.79e-06	1.05e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.78e-06	1.05e-05	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.76e-06	1.03e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—chronic obstructive pulmonary disease	1.76e-06	1.03e-05	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—chronic obstructive pulmonary disease	1.75e-06	1.03e-05	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—chronic obstructive pulmonary disease	1.74e-06	1.02e-05	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.73e-06	1.01e-05	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.72e-06	1.01e-05	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—chronic obstructive pulmonary disease	1.72e-06	1.01e-05	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—chronic obstructive pulmonary disease	1.72e-06	1.01e-05	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—chronic obstructive pulmonary disease	1.71e-06	1e-05	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.71e-06	1e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.71e-06	1e-05	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—chronic obstructive pulmonary disease	1.69e-06	9.91e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.68e-06	9.85e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.67e-06	9.79e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.66e-06	9.71e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—chronic obstructive pulmonary disease	1.65e-06	9.68e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.65e-06	9.67e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—chronic obstructive pulmonary disease	1.65e-06	9.67e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.65e-06	9.67e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.65e-06	9.65e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.63e-06	9.58e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.63e-06	9.54e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.61e-06	9.43e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.6e-06	9.38e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—chronic obstructive pulmonary disease	1.59e-06	9.32e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—chronic obstructive pulmonary disease	1.58e-06	9.27e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.57e-06	9.21e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.57e-06	9.21e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—chronic obstructive pulmonary disease	1.55e-06	9.11e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.55e-06	9.08e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.54e-06	9.03e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.54e-06	9.01e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.53e-06	8.98e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—chronic obstructive pulmonary disease	1.52e-06	8.94e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.52e-06	8.91e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.52e-06	8.89e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.5e-06	8.81e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.5e-06	8.8e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.49e-06	8.75e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—chronic obstructive pulmonary disease	1.49e-06	8.72e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.48e-06	8.67e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.48e-06	8.66e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.47e-06	8.62e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.47e-06	8.61e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.46e-06	8.56e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.45e-06	8.49e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.44e-06	8.45e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.44e-06	8.43e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—chronic obstructive pulmonary disease	1.43e-06	8.4e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.39e-06	8.15e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—chronic obstructive pulmonary disease	1.37e-06	8.05e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.35e-06	7.94e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.34e-06	7.86e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—chronic obstructive pulmonary disease	1.32e-06	7.76e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	1.32e-06	7.74e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.29e-06	7.58e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.28e-06	7.48e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—chronic obstructive pulmonary disease	1.27e-06	7.44e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.27e-06	7.43e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.26e-06	7.4e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.25e-06	7.33e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.23e-06	7.24e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.23e-06	7.21e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—chronic obstructive pulmonary disease	1.22e-06	7.14e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.22e-06	7.13e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.21e-06	7.09e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.21e-06	7.07e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.19e-06	6.95e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.18e-06	6.94e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—chronic obstructive pulmonary disease	1.17e-06	6.87e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NOS3—chronic obstructive pulmonary disease	1.16e-06	6.83e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.16e-06	6.83e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.15e-06	6.77e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.13e-06	6.63e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.11e-06	6.53e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.11e-06	6.49e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.1e-06	6.47e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.09e-06	6.38e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.07e-06	6.26e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.05e-06	6.16e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.01e-06	5.94e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—chronic obstructive pulmonary disease	9.61e-07	5.64e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—chronic obstructive pulmonary disease	9.27e-07	5.43e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—chronic obstructive pulmonary disease	8.96e-07	5.25e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—chronic obstructive pulmonary disease	8.2e-07	4.81e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	7.5e-07	4.4e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	7.18e-07	4.21e-06	CbGpPWpGaD
